

| <b>DDI</b>             | <b>Cases with thromboembolic events (n=1288), no. (%)</b> | <b>Controls without thromboembolic events (n=5144), no. (%)</b> | <b>Univariate OR (95% CI)</b> | <b>P value</b> | <b>Model 1<sup>a</sup> AOR (95% CI)</b> | <b>P value</b> | <b>Model 2<sup>b</sup> AOR (95% CI)</b> | <b>P value</b> | <b>Model 3<sup>c</sup> AOR (95% CI)</b> | <b>P value</b> | <b>Model 4<sup>d</sup> AOR (95% CI)</b> | <b>P value</b> |
|------------------------|---|---|-------------------------------|----------------|---|----------------|---|----------------|---|----------------|---|----------------|
| No DDI                 | 710 (55.1)  | 3531 (54.8)   | 1                             |                | 1                                       |                | 1                                       |                | 1                                       |                | 1                                       |                |
| CYP3A4/P-gp inhibitors | 349 (27.1)  | 1907 (29.6)   | 0.89<br>(0.77-1.03)           | 0.115          | 0.88<br>(0.76-1.02)                     | 0.081          | 0.89<br>(0.77-1.03)                     | 0.122          | 0.86<br>(0.74-0.996)                    | 0.044          | 0.87<br>(0.75-1.004)                    | 0.056          |
| CYP3A4/P-gp inducers   | 160 (12.4)  | 649 (10.1)  | 1.30<br>(1.07-1.59)           | 0.008          | 1.26<br>(1.03-1.54)                     | 0.024          | 1.27<br>(1.04-1.56)                     | 0.018          | 1.22<br>(0.997-1.50)                    | 0.053          | 1.23<br>(1.004-1.51)                    | 0.046          |
| Both                   | 69 (5.4)  | 345 (5.3)   | 0.99<br>(0.75-1.31)           | 0.967          | 0.97<br>(0.73-1.29)                     | 0.829          | 0.95<br>(0.72-1.27)                     | 0.746          | 0.95<br>(0.71-1.26)                     | 0.706          | 0.92<br>(0.69-1.23)                     | 0.578          |

AOR: adjusted odds ratio; CI: confidence interval; DDI: drug-drug interaction; OR: odds ratio.

<sup>a</sup> Adjusted for age, sex, income and comorbidities (hypertension, congestive heart failure, diabetes mellitus, COPD, malignancy, dyslipidaemia and PAOD).

<sup>b</sup> Adjusted for age, sex, income and high risk of stroke.

<sup>c</sup> Adjusted for age, sex, income, comorbidities (hypertension, congestive heart failure, diabetes mellitus, COPD, malignancy, dyslipidaemia and PAOD), medication use (warfarin, antiplatelet agents, calcium channel blockers, antihypertensive agents, hypoglycaemic agents, insulin, lipid-lowering agents, NSAIDs, proton pump inhibitors and corticosteroids).

<sup>d</sup> Adjusted for age, sex, income, high risk of stroke, medication use (warfarin, antiplatelet agents, calcium channel blockers, antihypertensive agents, hypoglycaemic agents, insulin, lipid-lowering agents, NSAIDs, proton pump inhibitors and corticosteroids).